View Item 

Show simple item record

Importance and hurdles to drug discovery for neurological disease

dc.contributor.authorBerger, Joseph R.en_US
dc.contributor.authorChoi, Dennisen_US
dc.contributor.authorKaminski, Henry J.en_US
dc.contributor.authorGordon, Mark F.en_US
dc.contributor.authorHurko, Oresten_US
dc.contributor.authorD'Cruz, O'Neillen_US
dc.contributor.authorPleasure, Samuel J.en_US
dc.contributor.authorFeldman, Eva L.en_US
dc.date.accessioned2015-04-02T15:12:37Z
dc.date.available2015-04-02T15:12:37Z
dc.date.issued2013-09en_US
dc.identifier.citationBerger, Joseph R.; Choi, Dennis; Kaminski, Henry J.; Gordon, Mark F.; Hurko, Orest; D'Cruz, O'Neill; Pleasure, Samuel J.; Feldman, Eva L. (2013). "Importance and hurdles to drug discovery for neurological disease." Annals of Neurology 74(3): 441-446.en_US
dc.identifier.issn0364-5134en_US
dc.identifier.issn1531-8249en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110873
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherChurchill‐Livingstoneen_US
dc.titleImportance and hurdles to drug discovery for neurological diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110873/1/ana23997.pdf
dc.identifier.doi10.1002/ana.23997en_US
dc.identifier.sourceAnnals of Neurologyen_US
dc.identifier.citedreferenceCapehart B, Bass D. Review: managing posttraumatic stress disorder in combat veterans with comorbid traumatic brain injury. J Rehabil Res Dev 2012; 49: 789 – 812.en_US
dc.identifier.citedreferenceVictor M, Ropper AH. Degenerative diseases of the nervous system. In: Victor M, Ropper AH, eds. Principles of neurology. 7th ed. New York, NY: McGraw‐Hill, 2001: 1106 – 1174.en_US
dc.identifier.citedreferenceHebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013; 80: 1778 – 1783.en_US
dc.identifier.citedreferenceCaffrey C, Sengupta M, Park‐Lee E, Harris‐Kojetin L. National Survey of Residential Care Facilities. Available at: http://www.cdc.gov/nchs/nsrcf/nsrcf_questionnaires.htm. Accessed June 11, 2013.en_US
dc.identifier.citedreferenceBrown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373 – 380.en_US
dc.identifier.citedreferenceMuntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke 2002; 33: 1209 – 1213.en_US
dc.identifier.citedreferenceGordon NF, Gulanick M, Costa F, et al. Physical activity and exercise recommendations for stroke survivors: an American Heart Association scientific statement from the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention; the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and the Stroke Council. Circulation 2004; 109: 2031 – 2041.en_US
dc.identifier.citedreferenceMurphy SM, Puwanant A, Griggs RC. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol 2012; 72: 481 – 490.en_US
dc.identifier.citedreferenceAlexander JC, Salazar DE. Modern drug discovery and development. In: Robertson D, ed. Clinical and translational science: principles of human research. London, UK: Academic Press, 2009: 361 – 380.en_US
dc.identifier.citedreferenceLedford H. Translational research: 4 ways to fix the clinical trial. Nature 2011; 477: 526 – 528.en_US
dc.identifier.citedreferenceUS Food and Drug Administration. Summary of NDA approvals & receipts, 1938 to the present. 2013. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm Accessed June 6, 2013.en_US
dc.identifier.citedreferenceMiller G. Is pharma running out of brainy ideas? Science 2010; 329: 502 – 504.en_US
dc.identifier.citedreferencePaul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9: 203 – 214.en_US
dc.identifier.citedreferenceDorsey ER, Thompson JP, Carrasco M, et al. Financing of U.S. biomedical research and new drug approvals across therapeutic areas. PLoS One 2009; 4: e7015.en_US
dc.identifier.citedreferenceDorsey ER, Vitticore P, De Roulet J, et al. Financial anatomy of neuroscience research. Ann Neurol 2006; 60: 652 – 659.en_US
dc.identifier.citedreferencePammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011; 10: 428 – 438.en_US
dc.identifier.citedreferenceKaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade 2000–2009. Clin Pharmacol Ther 2011; 89: 183 – 188.en_US
dc.identifier.citedreferenceKelland K. Analysis: Neuroscience under threat as Big Pharma backs off. Reuters; 2011. Available at: http://www.reuters.com/article/2011/02/11/us‐neuroscience‐pharma‐idUSTRE71A2E120110211 Accessed June 8, 2013.en_US
dc.identifier.citedreference.The brain drain. Pharmafile; 2012. Available at: http://www.pharmafile.com/news/172099/brain‐drain Accessed June 8, 2013.en_US
dc.identifier.citedreferenceHurko O. The uses of biomarkers in drug development. Ann NY Acad Sci 2009; 1180: 1 – 10.en_US
dc.identifier.citedreferenceLeppert D, Glanzman R. On being a neurologist in industry. Ann Neurol 2013; 73: 319 – 326.en_US
dc.identifier.citedreferenceDuchan E, Patel DR. Epidemiology of autism spectrum disorders. Pediatr Clin North Am 2012; 59: 27 – 43, ix–x.en_US
dc.identifier.citedreferenceCDC. Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61: 1 – 19.en_US
dc.identifier.citedreferenceHirtz D, Thurman DJ, Gwinn‐Hardy K, et al. How common are the “common” neurologic disorders? Neurology 2007; 68: 326 – 337.en_US
dc.identifier.citedreferenceMartin JA. Preterm births—United States, 2007. MMWR Surveill Summ 2011; 60 ( suppl ): 78 – 79.en_US
dc.identifier.citedreferenceJankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011; 26: 1149 – 1156.en_US
dc.identifier.citedreferenceLipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: 885 – 894.en_US
dc.identifier.citedreferenceLipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001; 17 ( suppl 1 ): s4 – s12.en_US
dc.identifier.citedreferenceHauser WA, Annegers JF. Epidemiology of epilepsy. In: Laidlaw JP, Richens A, Chadwick D, eds. Textbook of epilepsy. New York, NY: Churchill‐Livingstone, 1992: 23 – 45.en_US
dc.identifier.citedreferenceHauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453 – 468.en_US
dc.identifier.citedreferenceHauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population‐based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71: 576 – 586.en_US
dc.identifier.citedreferenceTaylor BC, Hagel EM, Carlson KF, et al. Prevalence and costs of co‐occurring traumatic brain injury with and without psychiatric disturbance and pain among Afghanistan and Iraq War Veteran V.A. users. Med Care 2012; 50: 342 – 346.en_US
dc.identifier.citedreferenceSaulle M, Greenwald BD. Chronic traumatic encephalopathy: a review. Rehabil Res Pract 2012;2012: 816069.en_US
dc.identifier.citedreferenceStern RA, Riley DO, Daneshvar DH, et al. Long‐term consequences of repetitive brain trauma: chronic traumatic encephalopathy. PM R 2011; 3 ( 10 suppl 2 ): S460 – S467.en_US
dc.identifier.citedreferenceNoonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 2009; 7: A12.en_US
dc.identifier.citedreferenceGuyer B, Freedman MA, Strobino DM, Sondik EJ. Annual summary of vital statistics: trends in the health of Americans during the 20th century. Pediatrics 2000; 106: 1307 – 1317.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Health, United States, 2011. 2012. Available at: http://www.cdc.gov/nchs/data/hus/hus11.pdf#fig33. Accessed June 6, 2013.en_US
dc.identifier.citedreferenceAdministration on Aging. Projected future growth of the older population 2012. Available at: http://www.aoa.gov/AoARoot/Aging_Statistics/future_growth/future_growth.aspx Accessed January 29, 2013.en_US
dc.identifier.citedreferenceWang HS. Dementia in old age. In: Smith LW, Kinsbourne M, eds. Aging and dementia. New York, NY: Spectrum, 1977: 1 – 4.en_US
dc.identifier.citedreferenceSchoenberg BS, Kokmen E, Okazaki H. Alzheimer's disease and other dementing illnesses in a defined United States population: incidence rates and clinical features. Ann Neurol 1987; 22: 724 – 729.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ana23997.pdf
Size:
193.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.